MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

Trial Identifier: D7900C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03489525
Start Date: May 2018
Primary Completion Date: March 2022
Study Completion Date: March 2022
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Greek Translation
Spanish Translation

Trial Locations

Country Location
AU Melbourne, AU, 3004
ES Badalona, ES, 08916
GR Athens, GR, 11528
US, AZ Phoenix, AZ, US, 85054
US, FL Jacksonville, FL, US, 32224
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MI Detroit, MI, US, 48201
US, MN Rochester, MN, US, 55905
US, NC Charlotte, NC, US, 28204
US, VA Fairfax, VA, US, 22031